Objective. Trials of rheumatoid arthritis (RA) treatments report the average response in
multiple outcome measures for treated patients. It is more clinically relevant to test whether …

Significant progress has been made in outcome measurement procedures for osteoarthritis (OA)
clinical trials, and guidelines have been established by the US Food and Drug …

Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there
is no widely used definition of remission that is stringent but achievable and could be …

Context Leflunomide is a reversible inhibitor of de novo pyrimidine synthesis shown to be
effective in a phase 2 trial in 402 patients with active rheumatoid arthritis (RA). Objective To …

Background Lack of standardization of outcome measures limits the usefulness of clinical
trial evidence to inform health care decisions. This can be addressed by agreeing on a …

Objective To evaluate the efficacy and safety of 2 dosage regimens of lyophilized certolizumab
pegol (a novel PEGylated anti–tumor necrosis factor agent) as adjunctive therapy to …

OBJECTIVE: This study, known as STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis),
evaluated the safety and efficacy of adalimumab (Humira), a fully human monoclonal …

Background: Certolizumab pegol is a PEGylated tumour necrosis factor inhibitor. Objective:
To evaluate the efficacy and safety of certolizumab pegol versus placebo, plus methotrexate (…

OMERACT is the acronym for an international, informally organized network initiated in
1992 aimed at improving outcome measurement in rheumatology. Chaired by an executive …

Objective Bisphosphonates have slowed the progression of osteoarthritis (OA) in animal
models and have decreased pain in states of high bone turnover. The Knee OA Structural …